News
RDY
74.02
+4.37%
3.10
Nestlé India And Dr. Reddy's To Form Joint Venture To Take Health Science Nutraceutical Portfolio To Consumers Across India And Other Agreed Territories
Benzinga · 10h ago
Dr. Reddy’s Forges Nutraceuticals JV; Leadership Changes
TipRanks · 12h ago
Nestlé and Dr. Reddy’s Forge Nutraceuticals JV
TipRanks · 12h ago
Dr. Reddy's Recalls Sapropterin Dihydrochloride Powder For Oral Solution
NASDAQ · 1d ago
Dr. Reddy’s Announces Urgent Medication Recall
TipRanks · 2d ago
Dr. Reddy’s Faces USFDA Hurdle for Biosimilar
TipRanks · 3d ago
Weekly Report: what happened at RDY last week (0415-0419)?
Weekly Report · 3d ago
Dr. Reddy’s Introduces Innovative IBS Digital Care Plan
TipRanks · 6d ago
Dr. Reddy’s Q4 and FY24 Financial Results Due
TipRanks · 6d ago
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
NASDAQ · 6d ago
India's Biocon developing its own version of Wegovy, clinical trial likely next year
India's Biocon developing its own version of Novo Nordisk's Wegovy, clinical trial likely year. Wall Street has forecast the market for obesity treatments reaching at least $100 billion by the end of the decade. Biocon is looking to grab a piece of the exploding weight-loss drug market.
Reuters · 04/18 16:20
Dr. Reddy’s Faces Tax Demand; Plans Appeal
TipRanks · 04/18 15:57
Dr. Reddy’s Divests Venezuelan Subsidiary Stake
Dr. Reddy’s Laboratories Ltd. Has announced the sale of its entire stake in its Venezuelan subsidiary. The Venezuelan subsidiary had no turnover and a negative net worth in the last financial year. The transaction is expected to be completed by April 17, 2024. RDY stock is down 2% in the past week.
TipRanks · 04/16 01:00
Weekly Report: what happened at RDY last week (0408-0412)?
Weekly Report · 04/15 09:05
Dr. Reddy’s Debuts Migraine Device in Europe
TipRanks · 04/11 08:42
Dr. Reddy's Launches Drug-Free Migraine Management Device Nerivio In Europe Following Successful Launch In India
Dr. Reddy's Laboratories Ltd. Announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany. The launch marks the company's entry into digital therapeutics in Europe. The device is approved by the U.S. Food and Drug Administration.
Benzinga · 04/10 11:08
Weekly Report: what happened at RDY last week (0401-0405)?
Weekly Report · 04/08 09:05
Dr. Reddy’s Expands Heart Failure Therapy in India
Dr. Reddy’s Laboratories Ltd. Has partnered with Bayer to distribute a second brand of the heart failure drug Vericiguat in India. The drug has the potential to reduce hospitalizations and cardiovascular deaths. The company is expected to be a major player in the Indian market.
TipRanks · 04/05 14:27
Dr. Reddy's Laboratories Ltd. And Bayer Entered Into A Partnership To Market And Distribute A Second Brand Of Vericiguat In India. Under The Terms Of This Agreement, Bayer Has Granted Non-Exclusive Rights To Dr. Reddy's Under The Brand Name Gantra
Dr. Reddy's and Bayer have entered into a partnership to market and distribute a second brand of Vericiguat in India. India has between 8-10 million people with heart failure. Bayer has granted non-exclusive rights to Dr.Reddy's under the brand name Gantra.
Benzinga · 04/05 13:46
Intra-Cellular files lawsuits challenging Caplyta generics
Healthcare Intra-Cellular files lawsuits challenging Caplyta generics. Shares fell for the third straight session on Tuesday. Biopharma announced multiple lawsuits against companies seeking approval for generics targeted at its lead product Caplyna. The lawsuits seek a stay order against a potential FDA approval.
Seeking Alpha · 04/02 19:38
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).